Weekly funding opportunities

[med-Research]

NCCN/Pfizer/Astellas: Enzalutamide in the Treatment of Prostate Cancer<https://cdn.pfizer.com/pfizercom/2021-04/NCCN%20Pfizer%20Astellas%20Enzalutamide%20RFP_Final.pdf?VersionId=GTnTnMA95kPVrcLrxzuX4F8.y22TvjVp>
The overall aim is to develop innovative, novel, and impactful studies that address unmet needs as well as support the design and performance of enzalutamide research in the treatment of prostate cancer. Clinical trials, prospective studies, and retrospective correlative studies of enzalutamide treatment trials or datasets are encouraged. It is hoped proposals submitted in response to this RFP will guide development of enzalutamide and its combination with other therapies. Studies with correlative endpoints will be accepted, and studies that retrospectively analyze biomarkers (tissue, liquid biopsy, and other approaches) within prospective trials or datasets will be accepted. The following are selected priority areas to encourage the development of novel treatment approaches because of their ability to impact the unmet needs for patients with potentially lethal prostate cancer:

  *   Earlier disease states
  *   Treatment and biology of oligometastatic disease
  *   Populations with unique vulnerabilities
  *   Innovative treatment strategies
  *   Specific disease settings in which enzalutamide may offer value
  *   Next generation imaging
  *   Biomarkers of enzalutamide response (including imaging)
  *   Strategies to improve the therapeutic index of enzalutamide
Letter of intent due May 14, 2021. Med-RA deadline to receive draft documents: May 3.

Community Engaged Research on Pregnancy Related and Associated Infections and Sepsis Morbidity and Mortality (UG3 / UH3 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-21-033.html>
The purpose of this FOA is to support interdisciplinary community-engaged research designed to reduce or eliminate infections and sepsis as causes of pregnancy- related or associated morbidity and mortality (PRAMM) in regions of the United States with high rates of maternal mortality. This FOA is to support research primarily focused on PRAMM health disparities in areas with highest maternal morbidity and mortality.
Due May 20, 2021. Med-RA deadline to receive draft documents: May 10.

NINDS Program Project Grant (P01 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/pa-files/PAR-21-181.html>
This funding opportunity announcement (FOA) is issued by the National Institute of Neurological Disorders and Stroke to enable submission of program project grant applications that propose to conduct innovative, interactive research to answer significant scientific questions that are important for the mission of NINDS, via a synergistic collaboration between outstanding scientists who might not otherwise collaborate. The program project grant is designed to support research in which the funding of several interdependent highly meritorious projects as a group offers significant scientific advantages over support of these same projects as individual research grants.
Standard dates apply. Expires May 8, 2024. Med-RA deadline to receive draft documents for May 25, 2021 standard date: May 12.

AAV Vector manufacturing for diseases affecting very small populations (R01) Clinical Trials Not Allowed<https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-21-034.html>
The Center for Biologics Evaluation and Research seeks to advance the development of gene therapies for diseases affecting very small populations, potentially even single individuals, by enhancing innovations in the manufacture of Adeno-associated virus (AAV) vectors.
Due May 28, 2021. Med-RA deadline to receive draft documents: May 17.

NIST Standards Services Curricula Development Cooperative Agreement Program (SSCD CAP)<https://www.grants.gov/web/grants/view-opportunity.html?oppId=332488>
The NIST Standards Services Curricula Development Cooperative Agreement Program (SSCD CAP) is seeking applications from eligible applicants to develop undergraduate and/or graduate level curricula to incorporate documentary standards, standards development, and standardization information and content into seminars, modules, courses, and learning resources. The recipients will work with NIST to strengthen education and learning about documentary standards, standards development, and standardization.
Due June 1, 2021. Med-RA deadline to receive draft documents: May 18.

Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01)
R01: Clinical Trial Optional<https://fsucomgrants.wordpress.com/2021/04/15/academic-industrial-partnerships-for-translation-of-technologies-for-diagnosis-and-treatment-r01/Clinical%20Trial%20Optional>
R01: Clinical Trial Not Allowed<https://grants.nih.gov/grants/guide/pa-files/PAR-21-166.html>
The purpose of these Funding Opportunity Announcements (FOAs) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. These FOAs specify a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate a solution to their chosen problem. They are expected to plan, design, and validate that the solution will be suitable for end users. Each partnership should include at least one academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk assessment, diagnosis, treatment, and/or monitoring of disease status.
These FOAs define “innovation” as likelihood to deliver a new capability to end users.
Standard dates apply. Expires January 8, 2024. Med-RA deadline to receive draft documents for June 5, 2021 standard date: May 24.

Research on Autism Spectrum Disorders (R03 / R21 / R01 Clinical Trial Optional)
R03<https://grants.nih.gov/grants/guide/pa-files/PA-21-199.html>
R21<https://grants.nih.gov/grants/guide/pa-files/PA-21-200.html>
R01<https://grants.nih.gov/grants/guide/pa-files/PA-21-201.html>
The purpose of these Funding Opportunity Announcements is to encourage research grant applications to support research designed to elucidate the etiology, epidemiology, diagnosis, and optimal means of service delivery in relation to Autism Spectrum Disorders.
Standard dates apply. Expires March 6, 2024. Med-RA deadline to receive draft documents for June 5, 2021 standard date: May 24; July 16, 2021 standard date: June 3.

Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R34 / R01 Clinical Trial Required)
R34 <https://grants.nih.gov/grants/guide/pa-files/PAR-21-211.html>
NIMH seeks applications for pilot projects to evaluate the preliminary effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden. In this pilot phase of effectiveness research, the trial should be designed to evaluate the feasibility, tolerability, acceptability, safety, and potential effectiveness of the approach; to address whether the intervention engages the target(s)/mechanisms(s) that is/are presumed to underlie the intervention effects; and to obtain preliminary data needed as a pre-requisite to a larger-scale effectiveness trial (e.g., comparative effectiveness study, practical trial) designed to definitely test the effectiveness of interventions to improve post-acute outcomes.
R01<https://grants.nih.gov/grants/guide/pa-files/PAR-21-210.html>
NIMH seeks applications for research projects to evaluate the effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions affecting youth, adults, and older adults. This Funding Opportunity Announcement (FOA) encourages clinical trials to establish the effectiveness and test hypotheses regarding moderators, mediators, and mechanisms of action of post-acute phase therapeutic and services interventions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden for promoting optimal longer-term outcomes.
Standard dates apply. Expires March 17, 2024. Med-RA deadline to receive draft documents for June 5, 2021 standard date: May 24; July 16, 2021 standard date: June 3.

Congressionally Directed Medical Research Programs
Epilepsy Research Program<https://cdmrp.army.mil/funding/erp>
Idea Development Award
Pre-application (required letter of intent): June 14. Full application: July 21.
Quality of Life Award
Pre-application (required letter of intent): June 14. Full application: July 21.
Research Partnership Award
Pre-application (required letter of intent): June 14. Full application: July 21.
Med-RA deadline to receive draft documents for full application: July 8.
Ovarian Cancer Research Program<https://cdmrp.army.mil/funding/ocrp>
Omics Consortium Award
Pre-application (required letter of intent): June 24. Full application: July 8.
Med-RA deadline to receive draft documents for full application: June 24 (due to July 4 holiday).
Peer Reviewed Alzheimer’s Research Program<https://cdmrp.army.mil/funding/prarp>
Convergence Science Research Award
Pre-application (required letter of intent): June 14. Full application: July 21.
Innovation in Care and Support Award
Pre-application (required letter of intent): June 14. Full application: July 21.
Research Partnership Award
Pre-application (required letter of intent): June 14. Full application: July 21.
Accelerating Diagnostic Research Award
Pre-application (required letter of intent): June 14. Full application: July 21.
Leveraging Approaches for Innovation in Care and Support Award
Pre-application (required letter of intent): June 14. Full application: July 21.
Med-RA deadline to receive draft documents for full application: July 8.
Prostate Cancer Research Program<https://cdmrp.army.mil/funding/pcrp>
Early Investigator Research Award
Pre-application (required letter of intent): June 17. Full application: July 1. Confidential letters of recommendation: July 7.
Physician Research Award
Pre-application (required letter of intent): June 17. Full application: July 1. Confidential letters of recommendation: July 7.
Med-RA deadline to receive draft documents for full application: June 21.
Translational Science Award
Pre-application (required letter of intent): July 15. Full application: July 29.
Health Disparity Research Award
Pre-application (required letter of intent): July 15. Full application: July 29.
Med-RA deadline to receive draft documents for full application: July 16.
Idea Development Award
Pre-application (required letter of intent): September 2. Full application: September 23.
Clinical Consortium Award
Pre-application (required letter of intent): September 2. Full application: September 23.
Med-RA deadline to receive draft documents for full application: September 13.
Data Science Award
Pre-application (required letter of intent): July 15. Full application: July 29.
Health Equity Research and Outcomes Improvement Consortium (HEROIC) Award
Pre-application (required letter of intent): July 15. Full application: July 29.
Med-RA deadline to receive draft documents for full application: July 19.
Spinal Cord Injury Research Program<https://cdmrp.army.mil/funding/scirp>
Clinical Trial Award
Pre-application: May 24, 2021. Invited full application: September 3, 2021.
Translational Research Award
Pre-application: May 24, 2021. Invited full application: September 3, 2021.
Investigator Initiated Research Award
Pre-application: May 24, 2021. Invited full application: September 3, 2021.
Med-RA deadline to receive draft documents for pre-application: May 11.
Tuberous Sclerosis Complex Research Program<https://cdmrp.army.mil/funding/tscrp>
Exporation Hypothesis Development Award
Pre-application (required letter of intent): June 17. Full application: July 8.
Idea Development Award
Pre-application (required letter of intent): June 17. Full application: July 8
Clinical Translational Award
Pre-application (required letter of intent): June 17. Full application: July 8.
Med-RA deadline to receive draft documents for full application: June 24 (due to July 4 holiday).

Pfizer: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Research<https://cdn.pfizer.com/pfizercom/2021-04/GMG_2021-RD-L_ATTR-CMResearchUS.pdf?VersionId=QexMsP6Qlge7jQW7.Qy3L1ea7ekSfswC>
Projects that will be considered for Pfizer support will focus on several or one specified area:

  *   Early identification, evaluation, diagnosis, prognosis and treatment
  *   Study of hereditary ATTR genotypes and phenotypes:
     *   Non-Val30Met genotypes
     *   Val122Ile, Thr60Ala, Val30Met, and others
  *   Mixed phenotypic manifestations (e.g. polyneuropathy and cardiomyopathy)
  *   Use of tafamidis in the clinical setting (i.e. real-world evidence)
Due June 9, 2021. Med-RA deadline to receive draft documents: May 26 (due to Memorial Day holiday).

Emergency Award: Social, Behavioral, and Economic Research on COVID-19 Consortium (U01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/pa-files/PAR-21-213.html>
The purpose of this FOA is to advance research on the impact of SARS-CoV-2 and associated mitigation efforts on individual, family, and community behavior and on how subsequent economic disruption affects health-related outcomes, with close attention to underserved and vulnerable populations. To address these questions, this FOA aims to form a research consortium to access, extract, integrate, share, and analyze existing data from various sources with broad population coverage including underserved and vulnerable populations. Examples of existing data include public health data; personal digital data; economic, labor, and commerce data; electronic health records (EHRs); claims data; and ongoing health, demographic, and social surveys. This FOA solicits applications for individual population research projects that will be linked to a Social, Behavioral, and Economic Research on COVID-19 Consortium Coordination Center (SBECCC) to foster collaboration and synergies across consortium member projects. Investigators will work with the SBECCC to enhance as well as share data resources used in proposed research both within the consortium as well as with others for health research purposes. The SBECCC will organize annual meetings of the consortium investigators to share results, foster harmonization among measures collected, identify new opportunities for interaction/collaboration, and share results with NIH and the public. Further, the SBECCC will support the development of reports and analyses summarizing and integrating the findings/products of the consortium.
Due June 9, 2021 and November 8, 2021. Med-RA deadline to receive draft documents for June 9, 2021 due date: May 26 (due to Memorial Day holiday).

Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R21 / R01 Clinical Trial not Allowed)
R21<https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-21-007.html>
R01<https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-21-006.html>
These Funding Opportunity Announcements solicit applications to innovate and develop the early stages of novel technologies that will enable greater than a one order of magnitude improvement in 1) DNA sequencing, and 2) methods for direct sequencing of the diversity of entire RNA molecules. Advances in genomics and more broadly in biomedical research have been greatly facilitated by cycles of technology innovation and disruption that have driven significant and sustained nucleic acid sequencing throughput and assembly quality increases combined with cost decreases and read quality improvements. The goal now is to dramatically advance DNA sequencing and direct RNA sequencing technologies at reasonable costs with the anticipation that significant exploratory innovation in any of these and related areas would make significant contributions to the mission of NHGRI and the field of genomics, including to many of NHGRI’s other technology development goals.
Due June 25, 2021; March 1, 2022; and February 1, 2023. Med-RA deadline to receive draft documents for June 25, 2021 due date: June 14.

Intramural – Extramural Collaboration for Drug Screening with Biofabricated 3-D Disease Tissue Models (UH2 / UH3 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-21-015.html>
The purpose of this Funding Opportunity Announcement (FOA) is to promote partnerships between intramural investigators at the NCATS 3-D Bioprinting Laboratory<https://ncats.nih.gov/bioprinting/work> and extramural researchers to jointly develop and demonstrate the use of 3-D biofabricated tissues for disease modeling and drug screening.
Due June 28, 2021. Med-RA deadline to receive draft documents: June 15.

3D Technologies to Accelerate HTAN Atlas Building Efforts (UH2 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-037.html>
Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) as a part of its Beau Biden Cancer Moonshot Initiative<https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative> invites submission of applications requesting support for projects that will accelerate cancer research. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP) as Recommendation I: Generation of Human Tumor Atlases. The overarching goal of this FOA is to accelerate research efforts conducted and led by the Human Tumor Atlas Network (HTAN, humantumoratlas.org) via the implementation of three-dimensional (3D) imaging technologies that will allow for a comprehensive view of the dynamic multidimensional ecosystems that define tumors in humans. Each project will lead to the multiplexed 3D characterization of at least one cancer transition investigated by the HTAN (pre-malignant to malignant, primary to metastatic, therapy responsive to resistant). The data and analytical tools generated through this FOA will be made available for use by the research and clinical communities through the activities of the HTAN Data Coordinating Center.
Due June 30, 2021 and November 22, 2021. Med-RA deadline to receive draft documents for June 30, 2021 due date: June 17.

To search for additional funding opportunities, please visit CoM’s unofficial funding opportunities blog<https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=>.


-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.fsu.edu/pipermail/com_funding_opportunities/attachments/20210416/e04653be/attachment.html>